Skip to main content
. 2018 Feb 1;13(2):e0191922. doi: 10.1371/journal.pone.0191922

Fig 2. Survival estimates of the cumulative risk of treatment failure by Pfmdr1 alleles in patients treated with AL and ASAQ in the randomisation phase.

Fig 2

Fig 2(A1-A3) represent the risk of PCR-adjusted recrudescence in participants who received AL harbouring by Pfmdr1 variant. Similarly, Fig 2(B1-B3) represents the risk of PCR-adjusted recrudescence in participants who received ASAQ by Pfmdr1 variants.